Details of the Drug Combinations

General Information of This Drug (ID: DM36PKZ)

Drug Name
PF-3758309   DM36PKZ
Synonyms PF-309
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

8 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
AT7519 + PF-3758309 DCXCTN2 AT7519 Ewing sarcoma (Cell Line: TC-71) [2]
GDC-0084 + PF-3758309 DC147GE GDC-0084 Ewing sarcoma (Cell Line: TC-71) [2]
PF-3758309 + Panobinostat DC663GT Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
PF-3758309 + Marizomib DCAWL16 Marizomib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
PF-3758309 + Ruxolitinib DCL4ERT Ruxolitinib Hodgkin lymphoma (Cell Line: L-1236) [3]
PF-3758309 + THAPSIGARGIN DCI0Y15 THAPSIGARGIN Hodgkin lymphoma (Cell Line: U-HO1) [3]
PMID25656651-Compound-5 + PF-3758309 DC710ZN PMID25656651-Compound-5 Ewing sarcoma (Cell Line: TC-71) [2]
SCH 727965 + PF-3758309 DCG3M3L SCH 727965 Ewing sarcoma (Cell Line: TC-71) [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DrugCom(s)

References

1 Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U S A. 2010 May 18;107(20):9446-51.
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.